In last trading session, Merck & Co. Inc. (NYSE:MRK) saw 9.64 million shares changing hands with its beta currently measuring 0.34. Company’s recent per share price level of $107.52 trading at -$0.72 or -0.67% at ring of the bell on the day assigns it a market valuation of $270.06B. That closing price of MRK’s stock is at a discount of -11.28% from its 52-week high price of $119.65 and is indicating a premium of 21.39% from its 52-week low price of $84.52. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.75 million shares which gives us an average trading volume of 7.37 million if we extend that period to 3-months.
For Merck & Co. Inc. (MRK), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 30 analysts covering the stock, 0 rated the stock as a Sell while 4 recommended an Overweight rating for the stock. 9 suggested the stock as a Hold whereas 17 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $1.94 in the current quarter.
Merck & Co. Inc. (NYSE:MRK) trade information
Upright in the red during last session for losing -0.67%, in the last five days MRK remained trading in the red while hitting it’s week-highest on Wednesday, 09/13/23 when the stock touched $107.52 price level, adding 1.96% to its value on the day. Merck & Co. Inc.’s shares saw a change of -3.09% in year-to-date performance and have moved -1.40% in past 5-day. Merck & Co. Inc. (NYSE:MRK) showed a performance of -1.11% in past 30-days. Number of shares sold short was 14.64 million shares which calculate 2.09 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $124.09 to the stock, which implies a rise of 13.35% to its current value. Analysts have been projecting $103.00 as a low price target for the stock while placing it at a high target of $135.00. It follows that stock’s current price would drop -25.56% in reaching the projected high whereas dropping to the targeted low would mean a gain of 4.2% for stock’s current value.
Merck & Co. Inc. (MRK) estimates and forecasts
Statistics highlight that Merck & Co. Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 0.17% of value to its shares in past 6 months, showing an annual growth rate of -59.76% while that of industry is -10.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 4.90% in the current quarter and calculating 6.80% increase in the next quarter.
16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $15.28 billion for the same. And 15 analysts are in estimates of company making revenue of $14.53 billion in the next quarter that will end on Dec 2023. Company posted $14.96 billion and $13.83 billion of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 2.10% while estimating it to be 5.10% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 25.60% during past 5 years. In 2023, company’s earnings growth rate is likely to be around 17.40% while estimates for its earnings growth in next 5 years are of 10.78%.
Merck & Co. Inc. is more likely to be releasing its next quarterly report on October 26 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Merck & Co. Inc. (NYSE:MRK)’s Major holders
Insiders are in possession of 0.09% of company’s total shares while institution are holding 77.65 percent of that, with stock having share float percentage of 77.72%. Investors also watch the number of corporate investors in a company very closely, which is 77.65% institutions for Merck & Co. Inc. that are currently holding shares of the company. Vanguard Group Inc is the top institutional holder at MRK for having 243.64 million shares of worth $26.2 billion. And as of Jun 29, 2023, it was holding 9.60% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 205.65 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 8.10% of outstanding shares, having a total worth of $22.11 billion.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 79.16 million shares of worth $8.51 billion or 3.12% of the total outstanding shares. The later fund manager was in possession of 60.41 million shares on Jun 29, 2023, making its stake of worth around $6.5 billion in the company or a holder of 2.38% of company’s stock.